Evidence map›Paper›PMID 33509278›Full record

ArticleTrials2021

Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study.

Niranjan S Karnik, Cynthia I Campbell, Megan E Curtis, David A Fiellin, Udi Ghitza, Kathryn Hefner, Yih-Ing Hser, R Kathryn McHugh, Sean M Murphy, Sterling M McPherson and 9 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Niranjan S KarnikDepartment of Psychiatry & Behavioral Sciences, Rush University Medical Center, 1645 West Jackson Blvd., Suite 600, Chicago, IL, 60612, USA. Niranjan_Karnik@rush.edu.ORCID http://orcid.org/0000-0001-7650-3008
Cynthia I CampbellDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.
Megan E CurtisDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA, 90025, USA.
David A FiellinYale School of Medicine, Internal Medicine, Program in Addiction Medicine, PO Box 208056, 333 Cedar Street, New Haven, CT, 06520-8056, USA.
Udi GhitzaNational Institute on Drug Abuse, National Institutes of Health, National Institute on Drug Abuse Center for Clinical Trials Network, 6001 Executive Blvd, Bethesda, MD, 20892, USA.
Kathryn HefnerYale School of Medicine, Internal Medicine, Program in Addiction Medicine, PO Box 208056, 333 Cedar Street, New Haven, CT, 06520-8056, USA.
Yih-Ing HserDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA, 90025, USA.
R Kathryn McHughDivision of Alcohol, Drugs and Addiction, McLean Hospital, & Department of Psychiatry, Harvard Medical School, McLean Hospital, Proctor House 3, 115 Mill St, Belmont, MA, 02478, USA.
Sean M MurphyDepartment of Population Health Sciences, Weill Cornell Medical College, 1300 York Avenue, New York, NY, 10065, USA.
Sterling M McPhersonWashington State University Elson S. Floyd College of Medicine, 412 E. Spokane Falls Blvd., Spokane, WA, 99202-2131, USA.
Landhing MoranNational Institute on Drug Abuse, National Institutes of Health, National Institute on Drug Abuse Center for Clinical Trials Network, 6001 Executive Blvd, Bethesda, MD, 20892, USA.
Larissa J MooneyDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA, 90025, USA.
Li-Tzy WuDuke University School of Medicine, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3903, Durham, NC, 27710, USA.
Dikla Shmueli-BlumbergThe Emmes Company, LLC, National Institute on Drug Abuse Data and Statistics Center and Clinical Coordinating Center, 401 N Washington St, Rockville, MD, 20850, USA.
Matisyahu ShulmanDepartment of Psychiatry, Columbia University Irving Medical Center & Department of Psychiatry, New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY, USA.
Robert P SchwartzFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD, 21201-5633, USA.
Kari A StephensDepartments of Family Medicine, Biomedical Informatics & Medical Education, University of Washington, Seattle, WA, 98195, USA.
Katherine E WatkinsRAND Corporation, 1776 Main Street, Santa Monica, CA, 90401-3208, USA.
John MarsdenAddictions Department, Division of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, DeCrespigny Park, Denmark Hill, London, SE5 8AF, UK.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ZACHARY Franklin MEISEL · 2015 to 2026
$20.7M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
Greater Southern California Node of the Clinical Trials NetworkUG1DA049435 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YIH-ING HSER · 2019 to 2026
$16.7M
Quantifying How Cocaine Users Respond to Fentanyl Contamination in CocaineUG1DA049467 · NIDA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Niranjan Subhash Karnik, ANTONIO A MORGAN-LOPEZ · 2019 to 2026
$11.2M
Clinical Trials Network: Mid-Atlantic Integrated Care Research CollaborativeUG1DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BIGELOW, GEORGE, SCHWARTZ, ROBERT P · 2015 to 2019
$11.0M
Employing eSBI in a Community-based HIV Testing Environment for At-risk YouthR01DA041071 · NIDA · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI GAROFALO, ROBERT, KARNIK, NIRANJAN SUBHASH · 2015 to 2019
$3.2M
Health and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use DisorderR01DA046721 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI MURPHY, SEAN M. · 2019 to 2022
$1.6M
Affective and Inflammatory Reactivity to Pain in Opioid Use DisorderR01DA045632 · NIDA · MCLEAN HOSPITAL · PI MCHUGH, REBECCA KATHRYN · 2019 to 2022
$1.5M
NCATS NIH HHS UL1 TR001863NCIPC CDC HHS R01 CE002999NIDA NIH HHS P30 DA040500NIDA NIH HHS R01 DA041071NIDA NIH HHS R01 DA045632NIDA NIH HHS R01 DA046721NIDA NIH HHS UG1 DA013034NIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA040314NIDA NIH HHS UG1 DA049435NIDA NIH HHS UG1 DA049467NIDA NIH HHS UG1-DA049467
6 · The paper itself

Abstract

backgroundA lack of consensus on the optimal outcome measures to assess the efficacy and effectiveness of interventions for the treatment of opioid use disorder (OUD) has hampered the pooling of research data for evidence synthesis and clinical guidelines. A core outcome set (COS) is a minimum set of outcome measures that are recommended for all studies of a particular condition. The National Drug Abuse Treatment Clinical Trials Network (CTN) Core Outcome Set for OUD (COS-OUD) is a development study to identify core constructs, meaningful outcomes, and their optimal measurement for all efficacy and effectiveness studies of OUD treatment and service delivery. METHODS/

designOverseen by an expert workgroup, a modified, stepwise, e-Delphi methodology will be used to gain consensus among a panel of clinical practitioners and researchers involved in the treatment of OUD, who are members of the CTN. Sequential rounds of anonymous, online questionnaires will be used to identify, rate the importance of, and refine a core outcome set. A consensus threshold will be achieved if at least 70% of the panel rate the measure as critical for inclusion in the COS-OUD. Where consensus is not reached or there are suggestions for new measures, these will be brought forward to a further round of review prior to a consensus meeting. Products from this study will be communicated via peer-reviewed scientific journals and conferences. DISCUSSION: This initiative will develop a COS for OUD intervention trials, treatment studies, and service delivery and will support the pooling of research and clinical practice data and efforts to develop measurement-based care within the OUD treatment cascade.

trial registrationhttp://www.comet-initiative.org/Studies/Details/1579.

Indexed as

Consensus Statements as TopicDelphi TechniqueNational Institute on Drug Abuse (U.S.)Opioid-Related DisordersResearch DesignAdolescentAdultAgedEndpoint DeterminationFemaleHumansMaleMiddle AgedTreatment OutcomeUnited StatesYoung AdultConsensusCore outcome setE-Delphi surveyOpioid use disorderOutcome reportingPatient-reported outcomes

Identifiers

PMID33509278
PMCPMC7841754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.